Last reviewed · How we verify
Zonisamide Capsules
At a glance
| Generic name | Zonisamide Capsules |
|---|---|
| Also known as | Convagran |
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Insomnia
- Taste change
- Weight loss
- Nausea
- Decreased appetite
- Dizziness/Fainting
- Tiredness/Fatigue
- Diarrhea
- Congestion
- Nervousness/anxiety
- Memory problems
Key clinical trials
- Noise-Induced Hearing Loss-Acute Exposure Treatment (UA) (PHASE2)
- Noise-Induced Hearing Loss-Acute Exposure Treatment (PHASE2)
- The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study (PHASE2)
- Fasting Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg (PHASE1)
- Fed Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg (PHASE1)
- Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism (PHASE3)
- Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study (NA)
- Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zonisamide Capsules CI brief — competitive landscape report
- Zonisamide Capsules updates RSS · CI watch RSS
- Ain Shams University portfolio CI